Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases

American Journal of Hematology

Volumn 76, Issue 3, 2004, Pages 275-278

  Higashi, Takehiro ^a   Tsukada, Junichi ^a   Kato, Chiaki ^b   Iwashige, Atsushi ^a   Mizobe, Takamitsu ^a   Machida, Shinichiro ^a   Morimoto, Hiroaki ^a   Ogawa, Ryosuke ^a   Toda, Yoko ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clonal evolution; CML; Imatinib mesylate

Indexed keywords

IMATINIB; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; DRUG EFFICACY; HUMAN; LEUKEMIA REMISSION; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BONE MARROW; CHROMOSOME ABERRATIONS; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PIPERAZINES; PLATELET COUNT; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER;

EID: 20844461336     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20096     Document Type: Article

References (15)

1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346(9):645-652.
2. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99(6):1928-1937.
3. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530-3539.
4. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002;53(369):369-381.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-1037.
6. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101(2):473-475.
7. le Coutre P, Tassi E, Varella GM, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
8. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2001;96(3):1070-1079.
9. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95(11):3498-3505.
10. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-880.
11. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99(9):3472-3475.
12. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16(11):2190-2196.
13. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-1042.
14. rd Annual Meeting of the American Society of Hematology, Orlando, Florida, December 7-11, 2001. Washington, DC: American Society of Hematology; 2001. Abstract 584.
15. Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2003;88(2):227-229.